Gene Predictis Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
4
Gene Predictis General Information
Description
Developer of polygenic and multifactorial risk scores intended for interpreting complex genetic data. The company develops precision medicines and other diagnostic tools based on genetics that allow tailored treatments to improve drug treatment efficacy and significantly reduce harmful side effects resulting from adverse drug reactions for patients, thus providing physicians with genetic and molecular microbiology analyses for precise clinical results.
Contact Information
Website
www.genepredictis.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Parent Company
Primary Office
- EPFL Innovation Park
- Building B
- 1015 Lausanne
- Switzerland
+41 021 000 00 00
Gene Predictis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Gene Predictis Patents
Gene Predictis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3333267-A1 | Method and kit for predicting the risk of deep vein thrombosis and pulmonary embolism | Inactive | 09-Dec-2016 | 0000000000 | 0 |
Gene Predictis Executive Team (4)
Gene Predictis Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000-00000 0000000 | Gene Predictis | Board Member | 000 0000 |
| 0000000 000000000 | Gene Predictis | Board Member | 000 0000 |
| 0000000 0000000000 | Gene Predictis | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 000000ç00 | Gene Predictis | Board Member | 000 0000 |
| 00000000 0000000 | Gene Predictis | Board Member & Strategic Advisor | 000 0000 |
Gene Predictis Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|